Initial Experience With Tafamidis Treatment for Transthyretin Amyloid Cardiomyopathy

Background: Transthyretin amyloid cardiomyopathy is a progressive disease with a poor prognosis. There had been no specific treatment for transthyretin amyloid cardiomyopathy until tafamidis received expanded approval in March 2019 in Japan. However, the clinical efficacy of tafamidis remains unknow...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Makiko, Imamura, Teruhiko, Hori, Masakazu, Ushijima, Ryuichi, Joho, Shuji, Kinugawa, Koichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Circulation Society 2020
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819654/
https://www.ncbi.nlm.nih.gov/pubmed/33693263
http://dx.doi.org/10.1253/circrep.CR-20-0062

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819654/
https://www.ncbi.nlm.nih.gov/pubmed/33693263
http://dx.doi.org/10.1253/circrep.CR-20-0062

Ejemplares similares